{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:34:02Z","timestamp":1781537642645,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13555-022-00703-3","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T10:03:01Z","timestamp":1647252181000},"page":"921-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced Effectiveness of Adalimumab Compared to Topical\/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)"],"prefix":"10.1007","volume":"12","author":[{"given":"Charles W.","family":"Lynde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam S.","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Ohson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Gagn\u00e9-Henley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Avadisian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"2","key":"703_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/0019-5154.62754","volume":"55","author":"RK Sivamani","year":"2010","unstructured":"Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E. Biological therapy of psoriasis. Indian J Dermatol. 2010;55(2):161\u201370.","journal-title":"Indian J Dermatol."},{"key":"703_CR2","unstructured":"MedlinePlus. Psoriasis, http:\/\/www.nlm.nih.gov\/medlineplus\/psoriasis.html. Accessed 5 Oct 2021."},{"issue":"5","key":"703_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","volume":"59","author":"S AlQassimi","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis\u2014comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566\u201371.","journal-title":"Int J Dermatol."},{"key":"703_CR4","unstructured":"Canadian Dermatology Association. Psoriasis. 2021. https:\/\/dermatology.ca\/public-patients\/skin\/psoriasis\/. Accessed 5 Oct 2021."},{"issue":"3","key":"703_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"703_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/acr.23743","volume":"71","author":"L Eder","year":"2019","unstructured":"Eder L, Widdifield J, Rosen CF et al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken). 2019;71(8):1084\u201391.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"703_CR7","unstructured":"Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. 2009. https:\/\/www.dermatology.ca\/wp-content\/uploads\/2012\/01\/cdnpsoriasisguidelines.pdf. Accessed 5 Oct 2021."},{"issue":"5","key":"703_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/1203475416655705","volume":"20","author":"Canadian Psoriasis Guidelines Addendum, C.","year":"2016","unstructured":"Canadian Psoriasis Guidelines Addendum, C. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009. J Cutan Med Surg. 2016;20(5):375\u2013431.","journal-title":"J Cutan Med Surg"},{"key":"703_CR9","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","volume":"9","author":"G Caiazzo","year":"2018","unstructured":"Caiazzo G, Fabbrocini G, Di Caprio R et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668.","journal-title":"Front Immunol"},{"issue":"3","key":"703_CR10","doi-asserted-by":"publisher","first-page":"E174","DOI":"10.1503\/cmaj.090631","volume":"185","author":"A Freiman","year":"2013","unstructured":"Freiman A, Barankin B. Psoriasis. CMAJ. 2013;185(3):E174.","journal-title":"CMAJ"},{"key":"703_CR11","unstructured":"Canadian Psoriasis Network. Biologics and Biosimilars. 2020. https:\/\/www.canadianpsoriasisnetwork.com\/psoriasis-treatment\/biologics\/. Accessed 24 Feb 2021."},{"issue":"8","key":"703_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2040622318772705","volume":"9","author":"P Sator","year":"2018","unstructured":"Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018;9(8):147\u201358.","journal-title":"Ther Adv Chronic Dis"},{"key":"703_CR13","unstructured":"AbbVie Corporation. Product monograph. Humira (Adalimumab). https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/products\/HUMIRA_PM_EN.pdf. Appearance to 21 April 2021. Accessed 5 Oct 2021."},{"issue":"3","key":"703_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"J-H Saurat","year":"2008","unstructured":"Saurat J-H, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558\u201366.","journal-title":"Br J Dermatol"},{"issue":"3","key":"703_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","volume":"7","author":"A Menter","year":"2017","unstructured":"Menter A, Tha\u00e7i D, Wu JJ et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7(3):365\u201381.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"703_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1111\/jocd.12868","volume":"18","author":"X Guan","year":"2019","unstructured":"Guan X, Zhang CL. An update on clinical safety of adalimumab in treating psoriasis: a systematic review and meta-analysis based on 20 randomized controlled trials. J Cosmet Dermatol. 2019;18:1550\u20139.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"703_CR17","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dandet N. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"5","key":"703_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s13555-020-00435-2","volume":"10","author":"AG Wu","year":"2020","unstructured":"Wu AG, Conway J, Barazani L, Roy B, Cline A, Pereira F. Is clear always clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician\u2019s Global Assessment (PGA) in psoriasis clearance. Dermatol Ther (Heidelb). 2020;10(5):1155\u201363.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"703_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","volume":"66","author":"K Gordon","year":"2012","unstructured":"Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"703_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40257-015-0161-5","volume":"17","author":"KA Papp","year":"2016","unstructured":"Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systemic therapy: a pooled post hoc analysis of results from three double-blind, placebo-controlled clinical trials. Am J Clin Dermatol. 2016;17(1):79\u201386.","journal-title":"Am J Clin Dermatol."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00703-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:05:43Z","timestamp":1650535543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00703-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}